Experimental Hematology
Volume 37, Issue 7 , Pages 784-790, July 2009

Proteomics-based prediction of clinical response in acute myeloid leukemia

  • Maher Albitar

      Affiliations

    • Quest Diagnostics Nichols Institute, San Juan Capistrano, Calif., USA
    • Corresponding Author InformationOffprint requests to: Maher Albitar, M.D., Quest Diagnostics, Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA 92690-6130
  • ,
  • Steven J. Potts

      Affiliations

    • Aperio Technologies, Vista, Calif., USA
  • ,
  • Francis J. Giles

      Affiliations

    • Division of Hematology, Cancer Therapy and Research Center, University of Texas, Health Science Center, San Antonio, Tex., USA
  • ,
  • Susan O'Brien

      Affiliations

    • Leukemia Department, M.D. Anderson Cancer Center, University of Texas, Houston, Tex., USA
  • ,
  • Iman Jilani

      Affiliations

    • Quest Diagnostics Nichols Institute, San Juan Capistrano, Calif., USA
  • ,
  • Amber C. Donahue

      Affiliations

    • Quest Diagnostics Nichols Institute, San Juan Capistrano, Calif., USA
  • ,
  • Elihu H. Estey

      Affiliations

    • Leukemia Department, M.D. Anderson Cancer Center, University of Texas, Houston, Tex., USA
  • ,
  • Hagop Kantarjian

      Affiliations

    • Leukemia Department, M.D. Anderson Cancer Center, University of Texas, Houston, Tex., USA

Received 28 June 2008; received in revised form 27 January 2009; accepted 4 March 2009. published online 17 April 2009.

Objective

Response to chemotherapy is achieved in 60% to 70% of patients with acute myeloid leukemia. The ability to predict responders may help in stratifying patients and exploring different therapeutic approaches for nonresponders. Proteomics methods were used to search for predictive factors or combinations of factors.

Materials and Methods

Peripheral blood plasma samples from 41 patients with confirmed acute myeloid leukemia with intermediate or poor cytogenetics were obtained prior to induction therapy for proteomic analysis. For each plasma sample, four fractions eluted from a strong anion column were applied to 3 different ProteinChip array surfaces and 12 surface-enhanced laser desorption/ionization spectra were generated. Peaks that correlated with response were identified, and decision trees incorporating these peaks along with various clinical and laboratory findings were constructed to predict response.

Results

Multiple decision trees were constructed. One peak, when combined with age, provided strong positive prediction of responders with 83% accuracy. A second tree, which combined one peak with both cytogenetics and the percent of monocytes in peripheral blood, detected responders with 95% accuracy. A third peak was adequate to predict responders in the intermediate cytogenetic group with 86% accuracy.

Conclusions

Proteomic analysis should be further explored to define factors important in predicting clinical response in patients with acute myeloid leukemia.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0301-472X(09)00129-5

doi:10.1016/j.exphem.2009.03.011

Experimental Hematology
Volume 37, Issue 7 , Pages 784-790, July 2009